Angiogenesis (clinical trials)

Canadian Journal of Cardiology

Volumn 17, Issue 5 SUPPL. A, 2001, Pages

  Laham, Roger ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Clinical trials; Collateral circulation; Coronary disease; Growth substances; Ischemia

Indexed keywords

ANGIOGENIC FACTOR; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST STIMULATING FACTOR 1; FIBROBLAST STIMULATING FACTOR-1; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANGIOGENESIS INDUCING AGENTS; COLLATERAL CIRCULATION; CORONARY DISEASE; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOMIZED CONTROLLED TRIALS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035347548     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Atwood JE, Myers J, Colombo A, et al. The effect of complete and incomplete revascularization on exercise variables in patients undergoing coronary angioplasty. Clin Cardiol 1990;13:89-93.
2. de Feyter PJ. PTCA in patients with stable angina pectoris and multivessel disease: is incomplete revascularization acceptable? Clin Cardiol 1992;15:317-22.
3. Levin DC, Beckmann CF, Sos TA, Sniderman K. Incomplete myocardial reperfusion despite a patent coronary bypass: a generally unrecognized shortcoming of the surgical approach to coronary artery-disease. Radiology 1982;142:317-21.
4. McNeer JF, Conley MJ, Starmer CF, et al. Complete and incomplete revascularization at aortocoronary bypass surgery: experience with 392 consecutive patients. Am Heart J 1974;88:176-82.
5. Babaei S, Teichert-Kuliszewska K, Monge JC, Mohamed F, Bendeck MP, Stewart DJ. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998;82:1007-15.
6. Ishibashi H, Nakagawa K, Nakashima Y, Sueishi K. Conditioned media of carcinoma cells cultured in hypoxic microenvironment stimulate angiogenesis in vitro: relationship to basic fibroblast growth factor. Virchows Arch 1995;425:561-8.
7. Laham RJ, Rezaee M, Post M, et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000;292:795-802.
8. Unger EF, Banai S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994;266:H1588-95.
9. Sellke FW, Tofukuji M, Laham RJ, et al. Comparison of VEGF delivery techniques on collateral-dependent microvascular reactivity. Microvasc Res 1998;55:175-8.
10. Lopez JJ, Laham RJ, Stamler A, et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998;40:272-81.
11. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994;94:623-30.
12. Pearlman JD, Laham RJ, Simons M. Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation - preliminary study in pigs. Radiology 2000;214:801-7.
13. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-50.
14. Laham RJ, Sellke FW, Edelman ER, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase 1 randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865-71.
15. Henry TD. Double-blind, placebo-controlled trial of recombinant human vascular endothelial growth factor: VEGF in Ischemia for Vascular Angiogenesis (VIVA) Trial. American College of Cardiology 48th Scientific Session. New Orleans, March 7 to 10, 1999.
16. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-74.
17. 165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-4.
18. Laham RJ, Chronos NA, Leimbach M, et al. Results of a phase I open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFGF-2) in patients (Pts) with severe ischemic heart disease: 6 months follow-up. J Am Coll Cardiol 2000;35(Suppl A):73. (Abst 879-1)
19. Chronos NA. The FGF-2 Initiating Revascularization Support Trial (FIRST). American College of Cardiology 49th Scientific Session. Anaheim, March 12 to 15, 2000.
20. Laham RJ, Rezaee M, Post M, et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 1999;27:821-6.
21. 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery. J Am Coll Cardiol 1999;35:10A. (Abst)
22. Li J, Brown LF, Laham RJ, Volk R, Simons M. Macrophage-dependent regulation of syndecan gene expression. Circ Res 1997;81:785-96.